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SCIENTIFIC OPINION 
Scientific Opinion on Lipase from a Genetically Modified Strain of 
Aspergillus oryzae (strain NZYM-FL)1,2 
EFSA Panel on Food Contact Material, Enzymes, Flavourings and Processing Aids 
(CEF)3, 4 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The food enzyme considered in this opinion is a lipase (triacylglycerol lipase; EC 3.1.1.3) produced with a 
genetically modified strain of Aspergillus oryzae. The genetic modifications do not raise safety concern. The 
food enzyme contains neither the production organism nor recombinant DNA. The lipase is intended to be used 
in a number of food manufacturing processes, such as oils, fats and eggs processing. The dietary exposure was 
assessed on the basis of data retrieved from the EFSA Comprehensive European Food Consumption Database. 
The food enzyme did not induce gene mutations in bacteria nor chromosome aberrations in human lymphocytes. 
Therefore, there is no concern with respect to genotoxicity. The systemic toxicity was assessed by means of a 
90-day subchronic oral toxicity study in rodents. A No Observed Adverse Effect Level was derived, which 
compared with the dietary exposure results in a sufficiently high Margin of Exposure. The allergenicity was 
evaluated by searching for similarity of the amino acid sequence to those of known allergens. The Panel 
considered that the likelihood of food allergic reactions to the enzyme is low and therefore does not raise safety 
concern. Based on the genetic modifications performed, the manufacturing process, the compositional and 
biochemical data provided and the toxicological studies, this food enzyme does not raise safety concern under 
the intended conditions of use. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following a request from the European Commission, the CEF Panel on Food Contact Material, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on 
the food enzyme lipase (triacylglycerol lipase; EC 3.1.1.3) produced with the genetically modified 
Aspergillus oryzae strain NZYM-FL.  
The A. oryzae parental strain has a long history of use for the production of food enzymes. It has been 
modified in order to produce and secrete lipase and to prevent or decrease the production of 
undesirable secondary metabolites. The genetic modifications do not raise safety concern.  
The food enzyme contains neither the production organism nor recombinant DNA, given the limits of 
detection. 
The food enzyme has been characterised by determining the temperature and pH optima and the 
thermo-stability. Its composition is verified by measuring the content of protein, ash, water, heavy 
metals and Total Organic Solid. The A. oryzae parental strain has been modified in order to prevent 
the production of cyclopiazonic acid and to decrease the potential production of kojic acid. The 
absence of cyclopiazonic acid, β-nitropropionic acid and kojic acid was demonstrated, given the limits 
of detection.  
The food enzyme is intended to be used in a number food manufacturing processes, such as oils, fats 
and eggs processing. The typical uses and the use levels recommended for specific food processes 
have been provided. 
The estimated dietary exposure was calculated on the basis of data retrieved from the EFSA 
Comprehensive European Food Consumption Database. 
The genotoxicity of the food enzyme was assessed by means of two in vitro assays (gene mutations in 
bacteria and chromosome aberrations in human lymphocytes). The food enzyme, produced with the 
genetically modified A. oryzae strain NZYM-FL, did not induce gene mutations in bacteria with or 
without metabolic activation when tested under the conditions employed in the study as presented by 
the applicant. Neither did it induce chromosome aberrations in cultured human blood lymphocytes 
under the test conditions employed for this study. The systemic toxicity was assessed by means of a 
90-day subchronic oral toxicity study in rodents.  A No Observed Adverse Effect Level (NOAEL) was 
derived, which compared with the dietary exposure results in a sufficiently high Margin of Exposure.  
The CEF Panel considers that the likelihood of food allergic reactions to this lipase produced with this 
genetically modified strain of A.oryzae is low and therefore does not raise safety concern. 
Based on the genetic modifications performed, the manufacturing process, the compositional and 
biochemical data provided and the toxicological studies, the Panel concluded that this food enzyme 
does not raise safety concern under the intended conditions of use. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Only food enzymes included in the Union list may be placed on the market as such and used in foods, 
in accordance with the specifications and conditions of use provided for in Article 7 (2) of Regulation 
(EC) No 1332/20085 on food enzymes. According to Regulation (EC) No 1332/2008 on food 
enzymes, a food enzyme which falls within the scope of Regulation (EC) No 1829/20036 on 
genetically modified food and feed should be authorised in accordance with that Regulation as well as 
under this Regulation. 
An application has been introduced by the company Novozymes A/S for the authorisation of the food 
enzyme lipase from a genetically modified strain of Aspergillus oryzae (strain NZYM-FL). 
Following the requirements of Article 12.1 of Commission Regulation (EC) No 234/20117 
implementing Regulation (EC) No 1331/20088, the Commission has verified that the application falls 
within the scope of the food enzyme Regulation and contains all the elements required under Chapter 
II of that Regulation. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out the safety 
assessment on the food enzyme lipase from a genetically modified strain of Aspergillus oryzae (strain 
NZYM-FL) in accordance with the article 17.3 of Regulation (EC) No 1332/2008 on food enzymes. 
  
                                                     
5  Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 december 2008 on Food Enzymes and 
Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/199, Directive 2000/13/EC, Council 
Directive 2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, p. 7-15. 
6  Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically 
modified food and feed. OJ L 268, 18.10.2003 p. 1-23. 
7  Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the 
European Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes 
and food flavourings. OJ L 64, 11.03.2011, p. 15-24. 
8  Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a 
common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, p. 1-6. 
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ASSESSMENT 
1. Introduction 
Before January 2009 food enzymes other than those used as food additives were not regulated or were 
regulated as processing aids under the legislation of the Member States. On 20 January 2009 the 
Regulation (EC) No 1332/2008 on food enzymes entered into force. This Regulation applies to 
enzymes that are added to food to perform a technological function in the manufacture, processing, 
preparation, treatment, packaging, transport or storage of such food, including enzymes used as 
processing aids. The Regulation (EC) No 1331/2008 established Union procedures for the safety 
assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The 
use of a food enzyme shall only be authorised if it is demonstrated that:  
(i) it does not pose a safety concern to the health of the consumer at the level of use 
proposed;  
(ii) there is a reasonable technological need, and  
(iii) its use does not mislead the consumer.  
All food enzymes currently on the EU market and intended to remain on that market as well as all new 
food enzymes shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) 
and an approval via a Union list. 
The Guidance on submission of a dossier on a food enzyme for evaluation by EFSA (EFSA, 2009) 
lays down the administrative, technical and toxicological data required. 
In the case of enzymes produced with genetically modified microorganisms (GMM) the guidance on 
the risk assessment of GMM and their products intended for food and feed use (EFSA GMO Panel, 
2011) applies.  
The assessment of a GMM aims to evaluate the safety of the enzyme preparation related to the genetic 
modifications. This starts from the evaluation of the safety of the parental/recipient and donor strains, 
e.g. regarding their capability to produce undesirable metabolites. It also includes the assessment of 
the genetic modifications, specifically of the introduction of genes of concern and the genetic stability. 
Finally, the presence of the production organism and its recombinant DNA in the final product is 
assessed. Special attention is paid to the presence of any recombinant genes of concern (e.g. antibiotic 
resistance genes), introduced during the development of the production strain. If the absence of the 
production strain and the recombinant DNA has been confirmed, no extensive environmental risk 
assessment of the enzyme product is required. 
The following evaluation applies to the lipase (triacylglycerol lipase; EC 3.1.1.3) produced with a 
genetically modified strain of A.oryzae strain NZYM-FL. 
2. Information on existing authorisations and evaluations 
The applicant reports that the Danish and French authorities have evaluated and authorised the use of 
the food enzyme produced with the genetically modified A. oyzae strain NZYM-FL for oil and egg 
yolk processing. The Danish authority also provides the conditions of use, including the dosage to be 
added to specific foods that were up to a level of 40 LU/kg egg yolk and up to 0.5 KLU9/kg of oil. 
                                                     
9  (K)LU = (Kilo) Lipase Units (see Section 3.3) 
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3. Technical data 
3.1. Identity of the food enzyme 
IUBMB nomenclature:  Triacylglycerol lipase  
Systematic name:  Triacylglycerol acylhydrolase  
Synonym: Lipase 
IUBMB No:  EC 3.1.1.3  
CAS No:  9001-62-1  
EINECS No:  232-619-9. 
3.2. Chemical parameters 
The lipase produced with the genetically modified A. oryzae strain NZYM-FL is a single polypeptide 
chain of 274 amino acids. The molecular mass derived from the amino acid sequence was calculated 
to be 29.9 kDa.  
Data on the chemical parameters and the protein homogeneity status of the food enzyme have been 
provided for four food enzyme batches, three batches to be used for commercialisation and one batch 
(PPW 7023) used for the toxicological tests (Table 1). 
The average Total Organic Solids (TOS) of the four food enzyme batches was 9.3 % (w/w); the values 
ranged from 8.1 to 10.1 % (Table 1). TOS is a calculated value derived from 100 % minus % water 
minus % ash. The four food enzyme batches presented in Table 1 are concentrates without any added 
diluents.  
The average specific activity of the four food enzyme batches expressed as ratio enzyme activity/mg 
TOS was 0.217 KLU/mg TOS; the values ranged from 0.192 to 0.237 KLU/mg TOS (Table 1). 
Considering the low variability of the activities as well as the specific activities in the four food 
enzyme batches, the average activity/mg TOS value of 0.217 KLU/mg TOS was used for subsequent 
calculations. 
A. oryzae, as a species, is known to have the potential to produce undesirable secondary metabolites 
such as cyclopiazonic acid (CPA), β-nitropropionic acid (NPA) and kojic acid (KA) (Blumenthal, 
2004). Accordingly, these mycotoxins must be checked in the final food enzyme from A. oryzae 
(FAO/WHO, 2006). A. oryzae as a species belongs to the Aspergillus flavus group which is known to 
have a gene cascade for the biosynthesis of aflatoxins, but under any known fermentation conditions, 
A. oryzae strains never produced aflatoxins (Blumenthal, 2004; Lee et al., 1991). The parental strain 
has been modified by γ-irradiation mutagenesis, resulting in the deletion of gene clusters required for 
the synthesis of the mycotoxins cyclopiazonic acid (cpa) and aflatoxin (afl). UV irradiation 
mutagenesis resulted in a reduced potential (15 % of the original) to produce kojic acid. None of these 
three species-specific mycotoxins (CPA, NPA and KA) were detected in the food enzyme (Table 1) by 
mass spectrometry (LC-MS/MS).  
The protein homogeneity status of the food enzyme was also investigated by SDS-PAGE analysis. The 
apparent molecular mass based on this technique is about 36 kDa (compared to the calculated 
molecular mass of 29.9 kDa). According to the applicant, this is most likely due to glycosylation, a 
common feature of proteins of Aspergillus. The gels presented for the four food enzyme batches 
consistently showed a single protein band corresponding to a molecular mass of about 36 kDa. 
Lipase from Aspergillus oryzae strain NZYM-FL
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The food enzyme was tested for other enzyme activities, i.e. alpha-amylase, β-glucanase, protease and 
cellulase activities, which were below the detection limits of the employed methods, except for the 
β-glucanase activity (Table 1). 
Table 1:  Compositional data of the food enzyme 
Parameter Unit Batches 
  LMF 0006 LMF 0009 LMF 0010 PPW 7023(a) 
Lipase activity KLU/g batch(b) 21.1 22.0 18.7 18.2 
Protein % (w/w) 8.0 9.1 7.7 7.5 
Ash % (w/w) 3.6 3.8 3.4 3.5 
Water % (w/w) 86.3 86.9 88.5 87.0 
Toatal Organic 
Solids (TOS)(c) % (w/w) 10.1 9.3 8.1 9.5 
Activity/mg TOS KLU/mg TOS 0.209 0.237 0.231 0.192 
Pb mg/kg batch ND(d) ND(d) ND(d) ND(d) 
As mg/kg batch 0.26 ND(d) ND(d) ND(d) 
Cd mg/kg batch ND(d) ND(d) ND(d) ND(d) 
Hg mg/kg batch ND(d) ND(d) ND(d) ND(d) 
Antimicrobial 
activity  ND
(d) ND(d) ND(d) ND(d) 
Production strain CFU per g batch NA(e) NA(e) NA(e) ND(d) 
Cyclopiazonic 
acid mg/kg batch ND
(d) ND(d) ND(d) ND(d) 
Kojic acid mg/kg batch ND(d) ND(d) ND(d) ND(d) 
β-nitropropionic 
acid mg/kg batch ND
(d) ND(d) ND(d) ND(d) 
Antifoam mg/kg batch 930 950 840 850 
Alpha-amylase KNU(T)/g batch(f) ND(d) ND(d) ND(d) ND(d) 
β-glucanase BGU/g batch(g) 0.28 0.70 0.40 0.66 
Protease AU(A)/g batch(h) ND(d) ND(d) ND(d) ND(d) 
Cellulase ECU/g batch(i) ND(d) ND(d) ND(d) ND(d) 
(a): Batch used for the toxicological tests. 
(b): KLU: Kilo Lipase Units (see Section 3.3). 
(c): TOS calculated as 100 % - % water - % ash. 
(d): ND: Not detected: below the limits of detections (Pb: 1 mg/kg; As: 0.1 mg/kg; Cd: 0.05 mg/kg; Hg: 0.03 mg/kg; 
cyclopiazonic acid: 0.01 mg/kg; kojic acid: the limits of detection ranged from 0.01 to 0.04 mg/kg; β-nitropropionic 
acid: the limits of detection ranged from 0.40 to 1.1 mg/kg; alpha-amylase: 0.30 KNU(T); protease: 0.0011 AU(A)/g); 
cellulase: 30 ECU/g; antimicrobial activity: inhibition zone diameters ≤ 16 mm imply that the antimicrobial activity was 
absent (FAO/WHO, 2006)). 
(e): NA: Not analysed. 
(f): KNU(T): Kilo Novo alpha-amylase Units (relative to an internal enzyme standard “T”). 
(g): BGU: Beta-Glucanase Units. 
(h): AU(A): Anson Units (relative to an internal enzyme standard “A”). 
(i): ECU: Endo-Cellulase Units. 
 
The food enzyme complies with the microbiological criteria as laid down in the general specifications 
and considerations for enzymes used in food processing (FAO/WHO, 2006), which stipulate that 
Escherichia coli and Salmonella species are absent in 25 g of sample and total coliforms are not more 
than 30 CFU (Colony Forming Units) per gram.  
The applicant has provided information on the identity of the antifoam agents and the Panel considers 
the use of these as of no safety concern.  
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The provided data regarding compositional batch-to-batch-variability are considered sufficient. Table 
1 shows that the food enzyme batch PPW 7023 used for the toxicological assays has a similar 
activity/mg TOS, level of inorganic constituents and amount of antifoam agents in relation to the other 
three food enzyme batches (LMF). Consequently, this food enzyme batch (PPW 7023) is considered 
suitable for the toxicological testing.  
3.3. Properties of the food enzyme 
Triacylglycerol lipases catalyse the hydrolysis of the ester linkages in triacylglycerols, thus resulting in 
the generation of  free fatty acids, diacylglycerols, monoacylglycerols and glycerol. It also hydrolyses 
the sn-1-ester linkage of diacylphospholipids resulting in the formation of 2-acyl-1-lysophospholipid 
and free fatty acid. It does not require any co-factor.  
The enzymatic activity is quantified by using a pH-stat titration system and is expressed in Kilo Lipase 
Units/g (KLU/g). One LU is the amount of enzyme which releases 1 µmol of titratable butyric acid per 
minute under the given standard conditions (reaction conditions: pH = 7.0, T = 30 °C, reaction time, at 
least 1.5 minutes). One LU corresponds to the international definition of an enzyme unit. In the assay, 
tributyrin is used as substrate. Its cleavage results in butyric acid formation, which cause a pH 
variation. The reaction rate, and therefore the enzyme activity, are determined by measuring the 
volume of titrant added to the reaction system per minute to keep the pH constant.   
The food enzyme has been characterised regarding its activity depending on temperature and pH. The 
lipase is active at temperatures up to 70 °C (with an optimum at approximately 50 °C at pH 6) and 
within the pH-range of 4 to 10 (with an optimum of about pH 7 at 30 °C). The thermo-stability of the 
food enzyme was tested over the range of 15 °C to 90 °C after a pre-incubation at the different 
temperatures at pH 6 for 30 minutes. The activity itself was measured under standard conditions. The 
lipase retained its activity at temperatures up to 50 °C. At higher temperatures the food enzyme losses 
rapidly its activity (at 55 °C, 40 % residual activity, pre-incubation at pH 6 for 30 minutes) and above 
70 °C, no activity remains after 30 minutes. 
3.4. Information on the source materials 
3.4.1. Information relating to the genetically modified microorganism 
3.4.1.1. Characteristics of the recipient and parental microorganisms  
The production organism  is the fungus A. oryzae. A. oryzae strains are not qualified as QPS (Qualified 
Presumption of Safety) because of the potential of mycotoxin production (EFSA BIOHAZ, 2012). The 
parental strain, A. oryzae A1560, has a long history of use for the production of food enzymes. The 
recipient strain A. oryzae BECh2 has been developed from the parental strain, A. oryzae A1560, 
through a series of modification steps including classical mutagenesis and genetic modification (the 
latter not described for confidentiality reasons). 
The classical mutagenesis steps included γ-irradiation mutagenesis, resulting in the deletion of gene 
clusters required for the synthesis of the mycotoxins cyclopiazonic acid (cpa) and aflatoxin (afl), and 
UV irradiation mutagenesis, resulting in a drastically reduced potential (15 % of the original) to 
produce kojic acid. A Southern blot analysis confirmed the absence of antibiotic resistance genes 
which were used during the genetic modification of the recipient strain. 
3.4.1.2. Characteristics of the donor organisms  
The plasmid vector used for the transformation of the recipient strain contained elements to control the 
expression of the gene of interest as well as ensure integration of the introduced DNA into the 
recipient strain chromosome. The DNA introduced into the recipient strain did not contain antibiotic 
resistance genes.  
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3.4.1.3. Description of the genetic modification process  
The production strain A. oryzae NZYM-FL was developed from the recipient strain BECh2 through 
transformation with a plasmid vector and selection of the transformants on appropriate medium. 
The production strain differs from the recipient strain by the synthesis and secretion of lipase. 
3.4.1.4. Safety aspects of the genetic modification: Information relating to the GMM and comparison 
of the GMM with its conventional counterpart  
In comparison to the parental strain A1560, the recipient strain has lost the potential to produce 
cyclopiazonic acid and has a reduced potential to produce kojic acid. 
The final production strain NZYM-FL differs from the recipient strain by the synthesis and secretion 
of lipase.  
The presence of the gene encoding lipase in the NZYM-FL strain was verified by Southern blot 
analysis; this indicated that multiple copies of the full-length gene were integrated in the chromosomal 
DNA of the recipient. In order to estimate the number of copies, a quantitative real-time PCR was 
carried out.  
Southern analysis of the DNA production strain from three independent enzyme preparation batches at 
the end of pilot scale fermentation confirmed the genetic stability of the genetic modifications. 
The genetic modifications do not raise safety concern. 
3.4.1.5. Safety for the environment 
Neither the production strain nor its recombinant DNA were detected in the final product (see Section 
3.5.2). Accordingly, as the food enzyme belongs to Category 2 of the guidance on risk assessment of 
genetically modified microorganisms and their products (EFSA GMO Panel, 2011), environmental 
exposure to the genetically modified microorganism or its DNA is negligible and hence no further 
environmental risk assessment is required. 
3.5. Manufacturing process 
The manufacturing process includes a fermentation process and downstream processing. A 
comprehensive dataset related to the manufacturing process including a flow diagram was provided. 
The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/200410. 
According to the applicant the manufacturing process is certified according to Food Safety Systems 
Certification 22000 (FSSC 22000) and ISO 9001.  
3.5.1. Information relating to the fermentation process  
The food enzyme is produced by a pure culture in contained submerged fed-batch fermentation with 
conventional process controls in place. The identity and the purity of the culture are checked at each 
transfer step from frozen vials to the end of fermentation.  
3.5.2. Information relating to the downstream processing  
The downstream processing includes recovery, purification and concentration. The food enzyme 
produced is recovered from the fermentation broth after biomass separation via filtration. Further 
purification and concentration involve a series of filtration steps, including ultrafiltration and final 
germ filtration.  
                                                     
10  Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food 
additives. OJ L 226, 25.6.2004, p. 3-21. 
Lipase from Aspergillus oryzae strain NZYM-FL
 
EFSA Journal 2014;12(7):3762  10
The production strain could not be detected in a test volume of 1 g of three independent liquid batches 
tested in triplicate by liquid culturing in non-selective medium for 4 days (for resuscitation) followed 
by growth on selective solid agar plates for 4 days at suitable temperature favouring the growth of the 
production strain. No recombinant DNA was detected starting with 1 g of three samples of the 
concentrated product before formulation obtained from three independent production batches and 
tested in triplicate. Analysis was performed by PCR, amplifying the recombinant fragment spanning 
the deletion of an endogenous gene specific for the strain lineage, introduced in the first genetic 
modification step of the parental strain. 
3.6. Reaction and fate in food 
Triacylglycerol lipases catalyse the hydrolysis of the ester linkages in triacylglycerols. The hydrolysis 
of triacylglycerols results in the generation of free fatty acids, diacylglycerols, monoacylglycerols and 
glycerol. It also hydrolyses the sn-1-ester linkage of diacylphospholipids resulting in the formation of 
2-acyl-1-lysophospholipid and free fatty acid.  
The data and information provided indicate that the lipase is denatured during processing under the 
intended use conditions. The food enzyme was tested for other enzyme activities, i.e. alpha-amylase, 
β-glucanase, protease and cellulase activities, which were below the detection limits of the employed 
methods. Therefore, no unintended reaction products from the lipase and any side-activities are to be 
expected. 
3.7. Case of need and intended conditions of use 
The food enzyme is intended to be used in a number of food manufacturing processes. Typical uses 
provided by the applicant are listed in Table 2.  
Table 2:  Typical uses and recommended maximum use levels of the food enzyme as provided by the 
applicant 
Process Recommended dosage of the food enzyme 
Oils and fats processing 600 LU/kg of oils/fats, corresponding to 2.8 mg 
TOS/kg (600 LU/217 LU/mg TOS (217 is the average 
of four food enzyme batches)) 
Eggs processing 40 KLU/kg of egg yolks, corresponding to 184 mg 
TOS/kg (40000 LU/217 LU/mg TOS (217 is the 
average of the four food enzyme batches)) 
 
Its use during the oils and fats processing is aimed to improve the overall process, by reducing water 
consumption, increase the yield and the quality of the oil and improve its storage stability through 
efficient removal of phosphatides, also called gums. Lipase should be added to the aqueous phase in 
oil where it exerts its function by hydrolysing phospholipids; at the end it is removed as water based 
sludge.  
The use of the lipase during the eggs processing is aimed to hydrolyse phospholipids, resulting in 
better emulsifying properties, to increase the thermo-stability of the egg yolks and to allowing the use 
of higher pasteurisation temperatures for sauces and dressing. 
According to the applicant, the food enzyme is used at the minimum dosage necessary to achieve the 
desired reaction according to Good Manufacturing Practice (GMP). The dosage applied in practice by 
a food manufacturer depends on the particular process (see Table 2). 
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4. Dietary exposure 
The dietary exposure assessment is performed for the processes for which the food enzyme is intended 
to be used (Table 2). The human intake of foods produced with the food enzyme is that reported by the 
EFSA Comprehensive European Food Consumption Database11. 
In the case of oils and fats processing, the maximum recommended dosage is up to 0.6 KLU/kg 
oils/fats, corresponding to 2.8 mg TOS/kg vegetable oil (Table 2). A mean consumption of vegetable 
oil in 17 countries of 1.19 g /kg body weight (bw)/day was taken into account; therefore, the intake 
resulted to be 0.0033 mg TOS/kg bw/day ((1.19 x 10-3 kg vegetable oil /kg bw/day) x (2.8 mg TOS/kg 
vegetable oil)). 
In the case of egg processing, the maximum recommended dosage is 40 KLU/kg egg yolks, which 
corresponds to 184 mg TOS/kg egg yolks. In the EFSA Comprehensive European Food Consumption 
Database the mayonnaise was not reported, therefore, in order to consider a worst-case scenario, the 
consumption of prepared salads in Greece (2.31 g/kg bw/day) was taken into account. It was also 
assumed that 50 % of salads were mayonnaise and that it contains 10 % egg yolks treated with food 
enzyme, which means 0.12 g egg yolks kg bw/day treated with the food enzyme. The intake was then 
calculated to be 0.022 mg TOS/kg bw/day ((0.12 x 10-3 kg egg yolks/kg bw/day) x (184 mg TOS/kg 
egg yolks)). 
Finally, by adding the intakes calculated in both processing, the estimated dietary exposure can be 
calculated to 0.025 mg TOS/kg bw/day.  
In case the food enzyme is proposed for products particularly designed for infants or young children, 
ad hoc conservative exposure estimates must be made taking specifically into account these 
population groups. Otherwise, the very conservative approach described above, is considered to cover 
both adults and children. 
5. Toxicological data 
The toxicological assays were performed with a food enzyme (batch PPW 7023, see Table 1) 
representative of the other three food enzyme batches.  
Genotoxicity testing 
In order to investigate the potential to induce gene mutations in bacteria, an Ames test was performed 
according to OECD Test Guideline 471 (OECD, 1997a) and following Good Laboratory Practice 
(GLP) in four strains of Salmonella typhimurium (TA1535, TA100, TA1537, TA98) (treat and plate 
assay) and Escherichia coli WP2uvrA (plate incorporation assay), in the presence or absence of 
metabolic activation by S9 mix. Two experiments were carried out using six different concentrations 
of the food enzyme, appropriate positive controls and deionised water as a negative control. The 
highest concentration was 5 000 µg dry matter (ca. 3 650 μg TOS) per ml incubation mixture (treat 
and plate assay) or per plate (plate incorporation assay). All positive controls induced significant 
increases in revertant colony numbers, confirming the sensitivity of the tests and the efficacy of the S9 
mix, while the negative controls were within the normal ranges. Upon treatment with the food enzyme 
there was no increase in revertant colony numbers. Therefore, it was concluded that the food enzyme 
has no mutagenic activity, under the conditions employed.  
The in vitro chromosome aberration test carried out according to the OECD Test Guideline 473 
(OECD, 1997b) and following GLP. Cultured human peripheral blood lymphocytes, the division of 
which was stimulated with phytohaemagglutinin (PHA), were treated with purified water (negative 
control), the food enzyme or appropriate positive controls (4-nitroquinoline 1-oxide or 
                                                     
11  EFSA Comprehensive European Food Consumption Database http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.   
htm 
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cyclophosphamide in the absence or the presence of the S9 mix, respectively). Two experiments were 
performed. In the first experiment, applying 3 + 17 hours treatment, the cultures were exposed to the 
food enzyme (3 200, 4 000 and 5 000 µg food enzyme/ml, corresponding to ca. 300, 380 and 475 μg 
TOS/ml) for 3 hours either in the presence or the absence of the S9 mix. In the second experiment, the 
concentrations of the food enzyme tested were 3 613, 4 250 and 5 000 μg food enzyme/ml 
(corresponding to ca. 340, 400 and 475 μg TOS/ml); a 20 + 0 hours treatment, where cultures were 
exposed to the food enzyme for 20 hours without the S9 mix and a 3 + 17 hours treatment with the S9 
mix, were applied. In all cases the cells were harvested 20 hours after the beginning of treatment. Only 
cells with 44 to 46 chromosomes were considered. When tested in the presence of S-9 mix, the highest 
concentration of the food enzyme induced 1 % and 0 % mitotic inhibition in experiment 1 and 2, 
respectively, whereas 3 % mitotic inhibition were observed in the absence of S-9 mix in experiment 1 
but 22 % mitotic inhibition in experiment 2. These findings imply that prolonged treatment with the 
food enzyme at high concentrations affects the cell cycle.  For all food enzyme concentrations used, 
the frequency of cells with chromosomal aberrations was similar to that of negative controls (values of 
p ≤ 0.05 were considered as significant) except for one replicate of the highest concentration in 
experiment 1 in the absence of S-9 mix, where a small increase in cells with chromosomal aberrations 
was found. However, because this marginal increase was not observed in the other replicate and in 
experiment 2, it is not considered to be of biological significance. It was concluded that the food 
enzyme did not induce chromosomal aberrations in cultured human peripheral blood lymphocytes 
when tested up to 5 000 μg food enzyme/ml (corresponding to 475 μg TOS/ml) under the 
experimental conditions employed.  
Repeated dose toxicity testing 
A 90-day subchronic oral toxicity study was performed according to OECD Test Guideline 408 and 
following GLP (OECD, 1998). Four groups of 10 male and 10 female CD rats were given by gavage a 
dose of 10 ml/kg bw/day tap water (negative control) and three doses of the food enzyme equivalent to 
100, 340 and 1020 mg TOS/kg bw/day. 
One female receiving the highest dosage died during the 7th week of treatment. The macroscopic 
examination revealed perforation of the oesophagus and fluid in the thorax; the microscopic 
examination revealed oesophagitis, pleuritis and epicarditis. Because of these findings, the death was 
attributed to an injury of the oesophagus during administration of the test substance.  
Salivation was observed in some females and males after completion of the dosing, in particular in one 
male treated with the highest dose on one day during the 4th week.  
In haematological examination, a slight statistically significant increase in the Mean Cell Volume 
(MCV) in females treated with the lowest and the highest dosages was noticed. An increasing trend in 
the neutrophils was also observed in both sexes without however statistical significance in any group.  
In blood chemistry, a slight decrease of total cholesterol (not statistically significant) and albumin 
(statistically significant) concentrations and a statistically significant low albumin to globulin ratios in 
males receiving the highest dose were observed. Statistically significant lower calcium concentrations 
in males treated with the lowest and the highest doses, and statistically significant higher sodium and 
chloride concentrations in females receiving the middle and the highest dosages were also noted. The 
statistically significant decrease on calcium and albumin in the high dose males’ group in combination 
with some minor histopathological alterations in thymus were indicative of adverse effects at the 
highest dose level. Consequently, the Panel derived a NOAEL on the mid dose level of 340 mg 
TOS/kg bw/day.  
6. Allergenicity 
Potential allergenicity of lipase was assessed by comparing its amino acid sequence with those of 
known allergens according to the EFSA Scientific opinion on the assessment of allergenicity of GM 
plants and microorganisms and derived food and feed of the Scientific Panel on Genetically Modified 
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Organisms (EFSA GMO Panel, 2010). Using higher than 35 % identity in a window of 80 amino acids 
as the criterion, no match was found. No food allergic reactions to lipase have been reported in the 
literature. 
 
Consequently, the CEF Panel considers that the likelihood of food allergic reactions to this lipase 
produced with this genetically modified strain of A. oryzae is low and therefore does not raise safety 
concern.  
7. Discussion 
The parental strain A. oryzae A1560 has a long history of use for the production of food enzymes. The 
recipient strain, BECh2, was developed from the parental strain through a series of modification steps 
including classical mutagenesis and genetic modifications. The A.oryzae production strain NZYM-FL 
contains the chimeric lipase gene in multiple copies randomly integrated into the genomic DNA as 
part of the plasmid vector and the genetic modification has been proved to be stable. The introduced 
trait is well-known and does not trigger a safety concern. No sequences that cause concern were 
introduced. Neither the production strain nor the recombinant DNA were detected in the final products 
by methods considered adequate by the CEF Panel.  
The information provided on the manufacturing of the food enzyme, i.e. the fermentation conditions 
and the steps employed for isolation and purification, is considered sufficient. The available 
compositional data, including experimental evidence of the absence of potential contaminants such as 
mycotoxins, sufficiently demonstrate the identity and the purity of the food enzyme. The reported 
batch-to-batch variability is considered acceptable. 
Dietary exposure estimates were calculated by assuming that the food enzyme is used at its maximum 
recommended dosage and all the added food enzyme remains in the final food. Based on these 
assumptions and considering the total intake (Section 4), the estimated dietary exposure results to be 
0.025 mg TOS/kg bw/day. 
The food enzyme produced with the genetically modified A. oryzae strain NZYM-FL did not induce 
gene mutations in bacteria with or without metabolic activation. Neither did it induce chromosome 
aberrations in cultured human blood lymphocytes. Therefore, there is no concern with respect to 
genotoxicity. 
A comparison of the NOAEL (340 mg TOS/kg bw/day) from the 90-day study with the estimated 
dietary exposure, calculated to be 0.025 mg TOS/kg bw/day, results in a Margin of Exposure (MOE) 
of 13 600, which is found sufficient.  
The CEF Panel considers that the likelihood of food allergic reactions to this lipase from this 
genetically modified strain of A. oryzae is low and therefore does not raise safety concerns. 
CONCLUSIONS 
Based on the genetic modifications performed, the manufacturing process, the compositional and 
biochemical data provided and the toxicological studies, the food enzyme “Lipase from a genetically 
modified strain of Aspergillus oryzae (strain NZYM-FL)” does not raise safety concern under the 
intended conditions of use. 
DOCUMENTATION PROVIDED TO EFSA 
1. Dossier “Lipase from a genetically modified strain of Aspergillus oryzae (strain NZYM-FL)”. 
February 2013. Submitted by Novozymes A/S. 
2. Additional information received by Novozymes A/S on August 2013.  
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ABBREVIATIONS 
Afl   aflatoxin 
AU   Anson Units 
BGU   Beta-Glucanase Units 
bw   body weight 
CAS   Chemical Abstracts Service 
CFU   Colony Forming Units 
CPA   Cyclopiazonic acid 
DNA   Deoxyribonucleic acid 
EC   European Commission and Enzyme Commission 
ECU   Endo Cellulase Units 
EFSA   European Food Safety Authority 
EINECS  European Inventory of Existing Commercial Chemical Substances 
EU   European Union 
FAO   Food and Agricultural Organisation 
GLP   Good Laboratory Practice 
GMM   Genetically Modified Microorganisms 
GMO   Genetically Modified Organisms 
GMP   Good Manufacturing Practice 
PHA   Phytohaemagglutinin 
IUBMB  International Union of Biochemistry and Molecular Biology 
JECFA   Joint FAO/WHO Expert Committee on Food Additives 
KA   Kojic acid 
kDa   kilo Dalton 
KLU   Kilo Lipase Units  
KNU   Kilo Novo alpha-amylase Units 
LC-MS/MS  Liquid Chromatography/tandem Mass Spectrometry 
LU/g   Lipase Units per gran 
MCV   Mean Cell Volume 
MOE   Margin of Exposure 
MS   Mass Spectrometry 
NOAEL  No-Observed-Adverse-Effect Level 
NA    Not Analysed 
ND   Not Detected 
NPA   β-nitropropionic acid 
OECD   Organisation for Economic Cooperation and Development 
PCR   Polymerase Chain Reaction 
QPS   Qualified Presumption of Safety 
SDS-PAGE  Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
TOS   Total Organic Solids 
UV   Ultraviolet 
WHO   World Health Organisation 
 
